Daiki Tsuji
Shizuoka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study.
Journal: Investigational new drugs
Published: June 26, 2026
Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.
Journal: Cancer chemotherapy and pharmacology
Published: March 18, 2026
Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study.
Journal: British journal of clinical pharmacology
Published: January 27, 2026
NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts.
Journal: Cancer chemotherapy and pharmacology
Published: October 08, 2025
Analysis of intercellular lipids in the stratum corneum of patients with capecitabine-induced hand-foot syndrome: comparison with the stratum corneum of healthy individuals.
Journal: Cancer chemotherapy and pharmacology
Published: September 03, 2025
Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide.
Journal: British journal of clinical pharmacology
Published: February 16, 2025
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).
Journal: Scientific reports
Published: July 31, 2024
Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).
Journal: Cancer
Published: February 13, 2024
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I.
Journal: Investigational new drugs
Published: October 17, 2023
Changes in estimated glomerular filtration rate in patients administered proton pump inhibitors: a single-center cohort study.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: September 29, 2023
Influence of menopause on chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study.
Journal: Cancer medicine
Published: February 03, 2023
Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer.
Journal: European journal of clinical pharmacology
Published: May 20, 2022
Last Updated: 09/26/2026